Study Suggests Delta-Tocotrienol in Combination with Standard Therapy Increased Survival in Refractory Ovarian Cancer Patients
A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s benefits for cancer patients. Results of the open-label trial suggest that American River Nutrition-manufactured delta-tocotrienol in combination with bevacizumab had additive effects in chemotherapy refractory ovarian cancer, possibly conferred by the anti-angiogenic activity of both compounds. This is the first-ever clinical trial using tocotrienols in ovarian cancer patients.









0 Comments